首页> 美国卫生研究院文献>BMC Veterinary Research >Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results.
【2h】

Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results.

机译:玻璃体内低剂量庆大霉素注射液治疗马匹复发性或持续性葡萄膜炎的初步结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDespite appropriate medical therapy, many horses with equine recurrent uveitis continue to suffer from recurrent bouts of inflammation. Surgical intervention via the pars plana vitrectomy or suprachoroidal cyclosporine implant placement may control and/or prevent recurrences, however, these procedures may be contraindicated, unavailable, or declined by an owner. Thus, an effective adjunctive treatment option may help to improve the clinical outcomes in those situations. There are several anecdotal reports on the use of intravitreal gentamicin injections, but to date, no data evaluating the complication rate and/or treatment effect following this treatment have been published. Thus, the aim of this prospective study was to describe the intravitreal gentamicin injection technique, describe the associated peri-injection (within 24 h) and post-injection (30 to 780 days) complications, and to report the effects of the injection on the clinical signs of uveitis. Additionally, evaluation of the systemic and ocular Leptospira-status, and its effect on the treatment outcome was performed. A total of 86 horses of various ages, breeds, and gender presenting with recurrent or persistent uveitis were treated via intravitreal injection of 4 mg of undiluted gentamicin (0.04 ml, Genta 100, 100 mg/ml in 35 horses) or preservative-free gentamicin (0.05 ml, 80 mg/ml in 52 horses) under sedation and local anesthesia. All 86 horses were observed for immediate peri-injection and post-injection complications. Response to therapy was evaluated in 59 of the 86 horses (follow-up: 30 to 780 days).
机译:背景尽管进行了适当的药物治疗,许多马复发性葡萄膜炎的马仍然反复发作炎症。通过平面pars玻璃体切除术或脉络膜上环孢菌素植入物的植入进行的外科手术可以控制和/或预防复发,但是,这些方法可能是禁忌的,不可用的或被所有者拒绝。因此,在这些情况下,有效的辅助治疗选择可能有助于改善临床结局。关于玻璃体内庆大霉素注射液的使用,有几篇轶事报道,但迄今为止,尚未发表评估这种治疗后并发症发生率和/或治疗效果的数据。因此,这项前瞻性研究的目的是描述玻璃体内庆大霉素注射技术,描述相关的围注射(24小时内)和注射后(30至780天)并发症,并报道注射对庆大霉素的影响。葡萄膜炎的临床体征。此外,还对全身和眼部钩端螺旋体的状态及其对治疗结果的影响进行了评估。通过玻璃体内注射4μmg的未稀释庆大霉素(0.04μml,Genta 100、100μmg / ml在35匹马中)或不含防腐剂的庆大霉素,治疗了86例不同年龄,品种和性别的复发性或持续性葡萄膜炎马。 (在52匹马中,0.05µml,80µmg / ml)在镇静和局部麻醉下。观察全部86匹马的立即围注射和注射后并发症。在86匹马中,有59匹被评估了对治疗的反应(随访:30至780天)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号